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Abstract 
Ethnopharmacological relevance: Ludwigia octovalvis (Jacq.) P.H. Raven (Onagraceae) extracts have 
historically been consumed as a healthful drink for treating various conditions, including edema, 
nephritis, hypotension and diabetes. 
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Aim of the study: We have previously shown that Ludwigia octovalvis extract (LOE) can signiﬁcantly 
extend lifespan and improve age-related memory deﬁcits in Drosophila melanogaster through activating 
AMP-activated protein kinase (AMPK). Since AMPK has become a critical target for treating diabetes, 
we herein investigate the anti-hyperglycemic potential of LOE. 
Materials and methods: Diﬀerentiated C2C12 muscle cells, HepG2 hepatocellular cells, streptozotocin 
(STZ)-induced diabetic mice and high fat diet (HFD)-induced diabetic mice were used to investigate the 
anti-hyperglycemic potential of LOE. The open ﬁeld test and novel object recognition test were used to 
evaluate spontaneous motor activity and memory performance of HFD-induced diabetic mice. 
Results: In diﬀerentiated C2C12 muscle cells and HepG2 hepatocellular cells, treatments with LOE and 
its active component (β-sitosterol) induced signiﬁcant AMPK phosphorylation. LOE also enhanced 
uptake of a ﬂuorescent glucose derivative (2-NBDG) and inhibited glucose production in these cells. The 
beneﬁcial eﬀects of LOE were completely abolished when an AMPK inhibitor, dorsomorphin, was added 
to the culture system, suggesting that LOE requires AMPK activation for its action in vitro. In 
streptozotocin (STZ)-induced diabetic mice, we found that both LOE and β-sitosterol induced an anti-
hyperglycemic eﬀect comparable to that of metformin, a drug that is commonly prescribed to treat 
diabetes. Moreover, LOE also improved glycemic control and memory performance of mice fed a HFD. 
Conclusions: These results indicate that LOE is a potent anti-diabetic intervention that may have potential 
for future clinical applications. 
Keywords: glucose; insulin; β-sitosterol; AMPK 
1. Introduction 
An aging population is rapidly becoming a pressing issue for contemporary human society. Age-related 
diseases, such as metabolic syndrome, neurodegenerative diseases and cancer, pose enormous healthcare 
challenges and socioeconomic burdens. Dietary restriction (DR) is known to extend lifespan across 
species and to delay the onset of a variety of age-related diseases. However, it is impractical for humans 
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to adhere to a restricted diet for prolonged periods. Therefore, medications that mimic the eﬀect of DR are 
attractive as preventive or therapeutic avenues for treating age-related morbidities (Lopez-Lluch and 
Navas, 2016). 
Ludwigia octovalvis (Jacq.) P.H. Raven (Onagraceae) is a ﬂowering plant widely distributed in tropical 
areas around the world, and extracts from L. octovalvis (LOE) have traditionally been consumed as a 
healthful drink for treating various conditions, including edema, nephritis, hypotension and diabetes 
(Kadum Yakob et al., 2015; Ramirez et al., 2012). Our previous study showed that LOE and one of its 
active ingredients, β-sitosterol, signiﬁcantly extended the lifespan of fruit ﬂies (Drosophila melanogaster) 
through activating AMPK (Lin et al., 2014). The eﬀect is minimized in ﬂies fed on a low-calorie diet, 
suggesting that LOE acts in a manner similar to that of DR. Unlike DR, however, ﬂies treated with LOE 
do not exhibit reduced fecundity or other negative tradeoﬀs. LOE also attenuates age-related cognitive 
decline, both in ﬂies and in senescence-accelerated-prone 8 mice (Lin et al., 2014). In order to further 
explore the translational potential of LOE, we began the present study by demonstrating the eﬀect of LOE 
and β-sitosterol on AMPK activation and glucose handling in mammalian cellular models. AMPK is a 
major cellular energy sensor and metabolic regulator, and is considered to be a therapeutic target for 
treatment of diabetes mellitus (Coughlan et al., 2014). Indeed, metformin, one of the most frequently used 
drugs for diabetes, is an AMPK activator (Hardie et al., 2012; Zhou et al., 2001). We therefore examined 
the eﬀect of LOE on both streptozotocin (STZ)-induced and high-fat diet (HFD)-induced diabetic mice, 
representing type 1 and type 2 diabetic models, respectively. Our ﬁndings suggest that LOE is a 
promising candidate for the development of anti-diabetic medications with neuro-protective potential. 
2. Materials and methods 
 
2.1 LOE preparation and high performance liquid chromatography (HPLC) analysis 
Air-dried whole plants of L. octovalvis were obtained from the Hsiehyu Biotech Company Ltd., and a 
voucher specimen (No. 034) was deposited at the herbarium of Hsiehyu Biotech Company Ltd. LOE was 
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prepared as previously described (Lin et al., 2014). Brieﬂy, 100 g of L. octovalvis powder were soaked in 
400 ml of 70% ethanol overnight at 4 °C, and then extracted twice at 55 °C for 30 min. The supernatant 
was centrifuged (8000 × g for 5 min) and ﬁltered (TOYO No. 1) to remove debris. LOE was obtained 
following a decompression process. The chemical composition of LOE was analyzed by gas 
chromatography-mass spectrometry and was reported in the previously study (Lin et al., 2014). The 
concentration of β-sitosterol (1.19 ± 0.05 mg/g) was monitored using a HPLC instrument (SYKAM) 
equipped with a sample injector and a UV detector (205 nm). A C18 (Alltech Alltima™) column (4.6 × 
150 mm; 5 µm particle size) was used for β-sitosterol analysis and the mobile phase for the HPLC system 
consisted of 2.5% methanol in HPLC grade water with a constant ﬂow rate set at 1.2 ml/min. 
Representative HPLC chromatography traces for a β-sitosterol standard solution (Sigma-Aldrich) and a 
LOE sample are shown in Supplemental Fig. 1. 
2.2 Cell cultures 
 
Mouse muscle cells (C2C12) and hepatocellular cells (HepG2) were obtained from the Cell Bank of the 
Taiwan National Health Research Institute. C2C12 cells were grown as myoblasts in culture medium 
containing Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS), 100 U/ml penicillin G, and 100 μg/ml streptomycin. C2C12 myoblasts were then cultured in 
DMEM medium containing 2% horse serum to promote diﬀerentiation and fusion into myotubes, as 
described previously (Chou et al., 2013). HepG2 cells were grown at 37 ℃ in DMEM medium (Gibco), 
supplemented with 10% FBS (Biological Industries). Diﬀerent concentrations of LOE, β-sitosterol, 
metformin (Sigma-Aldrich) and/or dorsomorphin (Sigma-Aldrich) were added to culture medium for 12 
h. Cells were also incubated in 0.5x medium (1:1 dilution of the 1x medium in phosphate buﬀered saline, 
PBS) for 24 h to mimic a DR condition in vitro, as described previously (Lin et al., 2014). A lactate 
dehydrogenase assay (BioVision) and trypan-blue (Gibco) exclusion were used to monitor the survival of 
cells. 
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2.3 Western blot analysis 
Cells were lysed in radioimmunoprecipitation assay buﬀer (Thermo), and proteins were separated by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to polyvinylidene diﬂuoride 
membranes (Invitrogen), using standard procedures (Huang et al., 2015). The antibodies used were rabbit 
anti-phospho-AMPK (1:1000, Cell Signaling), rabbit anti-AMPK (1:500, Abcam) and mouse anti-α-
tubulin (1:500, GeneTex). Protein signals were visualized with horseradish peroxidase-conjugated 
secondary antibodies and ECL reagent (Thermo). The intensity of each target protein band was quantiﬁed 
using Image J software. 
2.4 Immunostaining and glucose uptake assay 
Diﬀerentiated C2C12 cells grown on cell culture chamber slides coated with Matrigel Basement 
Membrane Matrix (BD Matrigel™) were treated with diﬀerent concentrations of LOE, β-sitosterol, 
metformin, or grown under a DR condition (0.5x medium) for 24 h. Immunocytochemistry was 
performed as described previously (Wang et al., 2007). Cells were stained with primary polyclonal rabbit 
anti-Glut4 antibody (Abcam) overnight, and with secondary TRITC-conjugated goat anti-rabbit IgG 
(Abcam) for 1 h. Nuclei were labeled with 4′,6-diamidino-2-phenylindole (DAPI, The Jackson 
Laboratory), and images were captured using a Leica TCS SP5 confocal microscopy system (Leica) in the 
Imaging Core Laboratory of the Medical College, National Taiwan University. For the glucose uptake 
assay, drug-treated cells were exposed to 100 μg/ml 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol- 4-yl)Amino)-2-
Deoxyglucose (2-NBDG) dissolved in glucose-free, phenol red-free DMEM, for 20 min. Cells were then 
washed in PBS, and the ﬂuorescence of 2-NBDG was measured with a microplate reader at excitation and 
emission wavelengths of 485 nm and 535 nm, respectively. 
2.5 Glucose production assay 
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HepG2 cells were treated with diﬀerent concentrations of LOE, β-sitosterol, metformin, or were grown 
under a DR condition (0.5x medium) for 24 h. Afterwards, cells were exposed to the treatments described 
above in glucose-free, phenol red-free DMEM (Gibco), supplemented with 20 mM sodium lactate 
(Sigma-Aldrich) and 2 mM sodium pyruvate (Sigma-Aldrich), for 24 h. The cells were lysed in 0.5% 
Triton-X in PBS, and glucose concentration was measured by a glucose assay kit (Sigma-Aldrich). 
2.6 Animals and STZ-induced hyperglycemia 
All experimental protocols for animals followed the local animal ethics regulations and were approved by 
the National Taiwan University College of Medicine and College of Public Health Institutional Animal 
Care and Use Committee. Six to eight week-old male C57BL/6 mice were obtained from the National 
Taiwan University College of Medicine Laboratory Animal Center, and maintained in an animal room 
with controlled temperature (22–24 °C) and humidity (50–55%), under a 12 h light/dark cycle. All mice 
were fed ad libitum with powdered AIN-93 G diet (MP Biomedicals) or HFD, supplemented with various 
concentrations of LOE, β-sitosterol or metformin (Table 1). Food intake, water consumption and change 
in body weight of animals were monitored regularly. For STZ-induced hyperglycemia, mice were injected 
intraperitoneally with freshly prepared STZ (60 mg/kg in 0.01 M citrate buﬀer) daily for 5 days. Glucose 
levels were measured from tail blood samples, using a blood glucose meter (ACCU-CHEK Active, 
Roche). 
2.7 Glucose tolerance test (GTT) 
GTTs were performed after 8 weeks of LOE, β-sitosterol or metformin treatment. Mice were fasted for 6 
h and blood glucose concentration was measured at 0, 30, 60, 90, 120, and 180 min following 
intraperitoneal injection of glucose (2 g/kg). Area under the curve for the GTT was calculated using the 
trapezoidal rule. 
2.8 Behavioral tests 
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The open ﬁeld test was performed in an open box (40 cm × 40 cm × 40 cm). Each mouse was placed in 
the center of the open ﬁeld and was allowed to freely explore the apparatus for 30 min. Moving direction 
and travel distance for each mouse were recorded by automated observation (Singa technology). 
Immediately after the open ﬁeld test, mice were exposed two similar objects, and the time spent exploring 
each object was recorded during the subsequent 5-min period (deﬁned as the training session for the novel 
object recognition test). The mice were then returned to their home cage. Twenty-four hours later, the 
same animals were re-tested for 5 min in the box with a familiar and a novel object (deﬁned as the 
memory test session). The object dis-crimination index was calculated by subtracting the time spent on 
exploring a familiar object from the time spent on exploring a novel object, and dividing by total time 
spent exploring both objects. A higher score for the discrimination index indicates better memory 
performance in object recognition. 
3. Results 
 
3.1 LOE activates AMPK and enhances glucose uptake in C2C12 muscle cells 
To investigate the glycemic regulatory eﬀect of LOE, we began by evaluating the function of LOE on 
muscle cells in vitro. The viability of diﬀerentiated C2C12 muscle cells was unaﬀected by treatment for 
24 h with diﬀerent concentrations of LOE, β-sitosterol, metformin or by growth under a DR condition 
(0.5x medium), compared to controls (Fig. 1A). Higher doses of LOE and β-sitosterol signiﬁcantly 
enhanced AMPK phosphorylation, mimicking levels induced by treatments under a DR condition (0.5x 
medium) or metformin (Figs. 1B and 1C). These results are consistent with our previous study showing 
that LOE and β-sitosterol induce AMPK phosphorylation in Drosophila S2 cells (Lin et al., 2014). 
Importantly, this eﬀect was ameliorated by co-administration of dorsomorphin, an AMPK inhibitor (Figs. 
1D and 1E). AMPK activation in muscle cells induces translocation of glucose transporter type 4 (Glut4) 
to the plasma membrane to facilitate glucose uptake (Hardie et al., 2012; Richter and Hargreaves, 2013). 
Indeed, in contrast with vehicle-treated cells, we detected strong Glut4 immunoreactivity in the plasma 
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membrane of C2C12 cells following 24 h of LOE treatment (Fig. 1F). Moreover, LOE, β-sitosterol and 
metformin all dramatically increased the uptake of the ﬂuorescent glucose derivative, 2-NBDG (Fig. 1G). 
Glut4 translocation and 2-NBDG uptake were blocked when dorsomorphin was also present in the culture 
medium (Figs. 1F and 1G). These results strongly suggest that LOE may regulate glucose uptake in 
muscle cells through AMPK activation. 
3.2 LOE activates AMPK and attenuates glucose production in HepG2 cells 
In HepG2 cells, we also demonstrated that the viability of cells was not jeopardized by DR, LOE, β-
sitosterol, or metformin treatment, respectively (Fig. 2A). AMPK phosphorylation was induced by higher 
doses of LOE and β-sitosterol, analogous to our ﬁndings in C2C12 cells, and this eﬀect was abolished by 
co-administration of dorsomorphin (Figs. 2B-2E). As for the higher dose of metformin, LOE exhibited an 
inhibitory eﬀect on glucose production in HepG2 cells, an eﬀect that was also prevented by co-
administration of dorsomorphin (Fig. 2F). However, β-sitosterol inhibiting glucose production in these 
cells (Fig. 2F). 
3.3 LOE improves glycemic control in STZ-induced diabetic mice 
To test the eﬀect of LOE on systemic glucose homeostasis, the STZ-induced diabetic mouse model was 
used. These mice exhibit polyphagia, polydipsia, poor body weight gain, fasting hyperglycemia, 
hypoinsulinemia, and impaired glucose tolerance (Figs. 3A-3G), mimicking human type 1 diabetes. 
Treatment with either LOE or β-sitosterol led to partial improvement in polyphagia, polydipsia, hyper-
glycemia and glucose tolerance, similar to improvements observed in metformin-treated STZ mice (Figs. 
3B-3D and 3F-3G). Unlike some anti-diabetic drugs that act as insulin secretagogues, our treatments did 
not result in increased plasma insulin levels (Fig. 3E). 
3.4 LOE improves glycemic control and memory performance in HDF-induced diabetic mice 
We next tested the eﬀects of LOE in the HFD-induced diabetic mouse model, which exhibits exaggerated 
body weight gain, fasting hyperglycemia, and impaired glucose tolerance (Figs. 4Aand 4D-4F), 
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simulating human type 2 diabetes. LOE treatment corrected glucose intolerance and fasting 
hyperglycemia, but did not signiﬁcantly aﬀect food intake, water consumption or body weight in these 
mice (Figs. 4A-4C). 
Neurologic function is frequently impaired in patients with type 2 diabetes, thus we assessed motor and 
memory performance in these mice. Open ﬁeld tests showed no signiﬁcant diﬀerence in spontaneous 
motor activities among controls and HFD mice with or without LOE treatment (Figs. 5A and 5B). Control 
mice showed normal memory retention 2 h after training on the novel object recognition test, with a 
signiﬁcant decline 24 h after training (Figs. 5C and 5D). However, HFD mice already exhibited 
diminished memory performance 2 h after training compared to controls, and this deﬁcit was rescued by 
prior LOE treatment (Figs. 5C and 5D). Furthermore, the memory decay 24 h after training that was 
observed in control and HFD mice was abolished by LOE treatment (Figs. 5C and 5D). 
4. Discussion 
Our study provides in vitro and in vivo evidence for an anti-diabetic action of LOE. Liver and muscle are 
the major metabolic tissues involved in glucose homeostasis, and are responsible for glucose production 
and utilization, respectively. Diabetes mellitus is characterized by increased hepatic glucose production, 
as well as by impaired Glut4 glucose receptor translocation to the plasma membrane and decreased 
glucose uptake in muscle cells (Musi and Goodyear, 2006; Zierath et al., 1996). Both are counteracted by 
LOE in a cell-autonomous manner in our in vitro cellular models. In HepG2 cells, LOE activates AMPK, 
which is known to suppress expression of rate-limiting enzymes of hepatic gluconeogenesis, ie., glucose-
6-phosphatase and phosphoenolpyruvate carboxykinase (Foretz et al., 2005). This likely contributes to the 
reduced glucose production observed in our study. Indeed, inhibition of AMPK blocked the eﬀect of LOE 
on glucose production. Glucose uptake into skeletal muscle can be either AMPK- or insulin-dependent. 
The former usually occurs in a starved state or during muscle contraction, while the latter occurs in the 
fed state (Hardie et al., 2012; Musi and Goodyear, 2006). From our standpoint, the eﬀect of LOE on 
muscle cells appears to mimic the eﬀect of DR or exercise, both of which are beneﬁcial to multiple 
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aspects of physiology beyond glycemic control. Therefore, additional medical applications of LOE are 
worth future exploration. 
In line with our previous report on the eﬀect of LOE on Drosophila S2 cells (Lin et al., 2014), the present 
study indicates that evolutionarily conserved AMPK mediates, at least in part, the actions of LOE in 
various cell types. In addition, we have demonstrated that β-sitosterol, one of the active ingredients of 
LOE, contributes to AMPK activation in these cells. It is possible that AMPK in diﬀerent tissues works 
coordinately in response to intrinsic (e.g., FGF21) or extrinsic (e.g., LOE) factors to regulate systemic 
glucose metabolism (Salminen et al., 2017). Our cellular and animal studies ﬁt well with this picture, 
since LOE-treated diabetic mice exhibit improvements in both baseline glycemia and response to glucose 
loading. In addition to β-sitosterol, LOE is rich in polyphenols that may also contribute to glycemic 
control, and will be worthy of future investigation (Bozzetto et al., 2015; Lin et al., 2014; Tresserra-
Rimbau et al., 2016). 
Although AMPK activation was thought to be responsible for the metformin-induced inhibition of hepatic 
glucose production (Zhou et al., 2001), it has been shown that metformin is able to inhibit glucose 
production in AMPK-deﬁcient hepatocytes, and there is evidence that metformin can act to suppress 
hepatic gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase (Madiraju 
etal.,2014). Likewise ,although we have demonstrated that LOE induces AMPK phosphorylation in 
cellular models and attenuates hyperglycemia in diabetic mice, we cannot exclude the possibility that they 
exert the anti-hyperglycemic eﬀect through pathways independent of AMPK. AMPK activation can be 
achieved through diverse mechanisms (Hardie et al., 2012; Hawley et al., 2010), and the precise steps in 
LOE activation of AMPK are not known. Many phytochemicals such as resveratrol activate AMPK 
through inhibition of mitochondrial ATP synthesis, presumably as a strategy for plants to deter pathogens 
or herbivores (Hawley et al., 2010). Whether this is the case for LOE remains to be determined. 
Obesity is an important risk factor for diabetes mellitus, and control of body weight ameliorates insulin 
resistance (Musi and Goodyear, 2006). It is plausible that LOE alters the whole-body energy balance 
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through AMPK activation, thereby inducing a change in body weight (Lopez, 2017). However, the body 
weight trajectories of STZ-induced and HFD-induced diabetic mice showed no signiﬁcant diﬀerences 
between LOE-treated and control groups during the experimental period, suggesting that the eﬀects of 
LOE on glucose disposal are largely independent of body weight regulation. 
Patients with diabetes mellitus are at increased risk for a variety of neurologic complications, ranging 
from peripheral neuropathy to cognitive impairment (Gaspar et al., 2016; Mayeda et al., 2015; Stoeckel et 
al., 2016). Therefore, it would be a great beneﬁt for anti-diabetic treatment to also alleviate accompanying 
neurologic problems (Hasanvand et al., 2016). Relevant studies have been limited, and have given 
conﬂicting results. For instance, metformin was found to be detrimental to the spatial memory of old male 
mice in one study (Thangthaeng et al., 2017), whereas it prevented HFD-induced decline in spatial 
memory in another study(Allard et al., 2016). In addition, metformin use was reported to be associated 
with an increased risk of cognitive impairment in diabetic patients (Moore et al., 2013). Although the 
issue remains controversial, LOE is promising in this regard, since in the mouse model, it rescued the 
HFD-induced memory decline seen 2 h after training, and enhanced memory performance 24 h after 
training. Further studies are needed to conﬁrm these ﬁndings. 
5. Conclusions 
Our data indicate that LOE modulates AMPK signaling in multiple tissues and improves systemic glucose 
homeostasis. Furthermore, it exhibits memory-enhancing eﬀects in diabetic mice. Overall, these ﬁndings 
suggest that LOE is a promising nutraceutical for diabetic care. 
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Table 1. Dietary composition of mice receiving different drug treatments. 
 Group  
Composition (g/ Control LOE β-sitosterol Metfromin HFD HFD+  
kg)      LOE  
Casein lactic 200 200 200 200 200 200  
Soy oil 70 70 69.96 70 – –  
Lard – – – – 300 300  
Solka ﬂoc-40 50 50 50 50 50 50  
Dextrin 132 132 132 132 132 132  
Granular sugar 100 100 100 100 100 100  
AIN-93 mineral 35 35 35 35 35 35  
mix 
 
       
AIN-93 vitamin mix 10 10 10 10 10 10  
 L-Cystine 3 3 3 3 3 3 
 Choline bitartrate 2.5 2.5 2.5 2.5 2.5 2.5 
 LOE – 0.1 – – – 0.1 
 β-sitosterol – – 0.04 – – – 
 Metformin – – – 0.3 – – 
Figure 1. LOE and β-sitosterol induce AMPK phosphorylation and enhance glucose uptake in C2C12 
muscle cells. (A) LOE, β-sitosterol and metformin treatment do not aﬀect the viability of C2C12 muscle 
cells. (B and C) Representative Western blot and quantitative results show that LOE and β-sitosterol can 
induce AMPK phosphorylation. Reduced nutrients (0.5x medium) and metformin are known to activate 
AMPK, and are included as positive controls. (D and E) Representative Western blot and quantitative 
results show that LOE-induced AMPK phosphorylation is attenuated by an AMPK inhibitor 
(dorsomorphin). (F) LOE-induced glucose transporter type 4 (Glut4) translocation to the plasma 
membrane is blocked by dorsomorphin. (G) LOE-induced glucose uptake is blocked by dorsomorphin. 
Data are presented as mean ± SD (n = 3 for each group). * p < 0.05 compared to 1x medium or vehicle 
controls; # p < 0.05 compared to LOE by one-way ANOVA with Fisher's LSD post hoc test. 
 
Figure 2. LOE and β-sitosterol induce AMPK phosphorylation and reduce glucose production in HepG2 
cells. (A) LOE and β-sitosterol do not aﬀect the viability of HepG2 cells. (B and C) Representative 
Western blot and quantitative results show that LOE and β-sitosterol can induce AMPK phosphorylation. 
Reduced nutrients (0.5x medium) and metformin are known to activate AMPK and are included as 
positive controls. (D and E) Representative Western blot and quantitative results show that LOE-induced 
AMPK phosphorylation can be attenuated by an AMPK inhibitor (dorsomorphin). (F) LOE-induced 
reduced glucose production can be blocked by dorsomorphin. Data are presented as mean ± SD (n = 3–9 
for each group). * p < 0.05 compared to 1x medium or vehicle controls; # p < 0.05 compared to 100 
μg/ml LOE by one-way ANOVA with Fisher's LSD post hoc test. 
 
  
Figure 3. Anti-hyperglycemic activity of LOE and β-sitosterol on STZ-induced diabetic mice. (A) Body 
weight gain of normal control and STZ-induced diabetic mice with or without LOE or β-sitosterol added 
to the food. Metformin is an oral antidiabetic drug and is included as a positive control. Red arrow and 
black arrow indicate the time points of STZ injection and beginning of drug treatments, respectively. (B 
and C) LOE, β-sitosterol and metformin signiﬁcantly reduce food intake and water consumption of STZ-
induced diabetic mice. (D) LOE, β-sitosterol and metformin signiﬁcantly reduce fasting blood glucose of 
STZ-induced diabetic mice after 6 weeks of drug treatments. (E) Fasting plasma insulin levels are not 
aﬀected after 6 weeks of drug treatments. (F and G) Plasma glucose levels are measured during the GTT 
test in diﬀerent groups of mice. The area under the glycemic curves is signiﬁcantly lower after 6 weeks of 
LOE, β-sitosterol and metformin treatments compared to STZ group. Data are presented as mean ± SD (n 
= 8–9 for each group). * p < 0.05 compared Control; # p < 0.05 compared to STZ by one-way ANOVA 
with Fisher's LSD post hoc test. 
 
  
Figure 4. Anti-hyperglycemic activity of LOE on HFD-induced diabetic mice. (A) Body weight gain of 
normal control and HFD-induced diabetic mice with or without LOE added to the food. (B and C) LOE 
does not aﬀect food intake and water consumption of HFD-induced diabetic mice. (D) LOE signiﬁcantly 
reduces the fasting blood glucose of HFD-induced diabetic mice after 6 weeks of treatment. (E and F) 
Plasma glucose levels are measured during the GTT test in diﬀerent groups of mice. The area under the 
glycemic curves is signiﬁcantly lower after 6 weeks of LOE treatment compared to HFD group. Data are 
presented as mean ± SD (n = 8–9 for each group). * p < 0.05 compared Control; # p < 0.05 compared to 
STZ by one-way ANOVA with Fisher's LSD post hoc test. 
 
  
Figure 5. LOE enhances recognition memory of HFD-induced diabetic mice. (A and B) Representative 
moving path (A) and total travel distance (B) during the 30 min open ﬁeld test is shown. HFD and LOE 
treatment do not aﬀect general locomotor activity of mice. (C and D) The short-term (2 h after training) 
and long-term (24 h after training) recognition memory of mice was assessed using the novel object 
recognition (NOR) test. The time mice spent on both novel and familiar objects is shown in (C), and the 
discrimination index is presented in (D). LOE treatment signiﬁcantly enhances both short-term and long-
term recognition memory of HFD-induced diabetic mice. Data are presented as mean ± SEM (n = 5 for 
each group). *p < 0.05 compared to 2 h normal control among 3 diﬀerent dietary groups; # p < 0.05 
compared to 24 h normal control among 3 diﬀerent dietary groups; + p < 0.05 comparison between 2 and 
24 h in each dietary group by two-way ANOVA with Fisher's LSD post hoc test. 
 
